Venus Medtech (Hangzhou) First Half 2025 Earnings: CN¥0.31 loss per share (vs CN¥0.47 loss in 1H 2024)

Venus Medtech (Hangzhou) (HKG:2500) First Half 2025 Results

Key Financial Results

• Revenue: CN¥187.1m (down 19% from 1H 2024).
• Net loss: CN¥134.8m (loss narrowed by 35% from 1H 2024).
• CN¥0.31 loss per share (improved from CN¥0.47 loss in 1H 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Venus Medtech (Hangzhou) shares are down 21% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Venus Medtech (Hangzhou) (at least 1 which is potentially serious), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.